{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:42:15Z","timestamp":1761896535873,"version":"3.44.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.annder.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T22:01:26Z","timestamp":1491602486000},"page":"434-437","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u00c9rysip\u00e8le sans fi\u00e8vre ni syndrome inflammatoire lors d\u2019un traitement par tocilizumab"],"prefix":"10.1016","volume":"144","author":[{"given":"M.","family":"Y\u00e9l\u00e9h\u00e9-Okouma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Petitpain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.-L.","family":"Schmutz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2017.03.011_bib0100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.21847","article-title":"Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: twenty-four-week results of an open-label, clinical practice study","volume":"65","author":"Weinblatt","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.annder.2017.03.011_bib0105","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3899\/jrheum.141210","article-title":"Longterm safety of tocilizumab: results from 3\u00a0years of follow-up post-marketing surveillance of 5573\u00a0patients with rheumatoid arthritis in Japan","volume":"42","author":"Yamamoto","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0110","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/keq343","article-title":"Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials","volume":"50","author":"Campbell","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2017.03.011_bib0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3109\/s10165-011-0488-6","article-title":"Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab","volume":"22","author":"Hoshi","year":"2012","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0120","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2008.090068","article-title":"Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab","volume":"68","author":"Hirao","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2017.03.011_bib0125","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s10067-011-1827-x","article-title":"Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review","volume":"30","author":"Gout","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0130","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/s10165-011-0459-y","article-title":"Diagnostic features of mild cellulitis phlegmon in patients with rheumatoid arthritis treated with tocilizumab: a report of two cases","volume":"21","author":"Hirao","year":"2011","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0135","unstructured":"Plan gestion de risque de la sp\u00e9cialit\u00e9 pharmaceutique RoActemra\u00ae\u2013laboratoire Roche. In: http:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/deaabe4616246c03cf0f0706ad0b3257.pdf. [consult\u00e9 le 16\/12.2016]."},{"key":"10.1016\/j.annder.2017.03.011_bib0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.annder.2017.03.011_bib0145","article-title":"The absence of typical pneumonia symptoms in a patient with rheumatoid arthritis during tocilizumab and steroid treatment","volume":"2012","author":"Yanagawa","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.annder.2017.03.011_bib0150","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/rheumatology\/ker223","article-title":"Risk of infections in rheumatoid arthritis patients treated with tocilizumab","volume":"51","author":"Lang","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2017.03.011_bib0155","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3109\/s10165-008-0111-7","article-title":"Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases","volume":"19","author":"Fujiwara","year":"2009","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0160","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/rheumatology\/ker311","article-title":"IL-6\u00a0inhibition and infection: treating patients with tocilizumab","volume":"51","author":"Edwards","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.annder.2017.03.011_bib0165","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3899\/jrheum.100717","article-title":"Tocilizumab for rheumatoid arthritis: a Cochrane systematic review","volume":"38","author":"Singh","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.annder.2017.03.011_bib0170","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1136\/annrheumdis-2015-207838","article-title":"Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis","volume":"75","author":"Richter","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2017.03.011_bib0175","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2013-010423","article-title":"C reactive protein may not be reliable as a marker of severe bacterial infection in patients receiving tocilizumab","author":"Bari","year":"2013","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.annder.2017.03.011_bib0180","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1136\/annrheumdis-2016-209429","article-title":"Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.annder.2017.03.011_bib0185","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/INF.0b013e318295a3d0","article-title":"Procalcitonin: a marker of infection not subverted by treatment with interleukin-6\u00a0receptor inhibition","volume":"32","author":"Gaensbauer","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.annder.2017.03.011_bib0095","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1136\/annrheumdis-2016-209773","article-title":"Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs","volume":"76","author":"Strangfeld","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817301394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0151963817301394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:05:20Z","timestamp":1758971120000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0151963817301394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":19,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0151963817301394"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2017.03.011","relation":{},"ISSN":["0151-9638"],"issn-type":[{"type":"print","value":"0151-9638"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00c9rysip\u00e8le sans fi\u00e8vre ni syndrome inflammatoire lors d\u2019un traitement par tocilizumab","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}